Non Small Cell Lung Cancer Prognosis by Transcriptional Profiling

The invention is a biomarker test for the accurate prognosis of lung adenocarcinoma. A 37-gene survival signature has been discovered that has a predictive accuracy of .96 as measured by the area under the time-dependent receiver operating curves. The gene signature is able to place a patient into one of three indicative groups for individual treatment. Additionally, a 12-gene signature correctly predicts the stage of 94.2% of patients.

Intellectual Property Status
Disclosure 388. Patent Pending

Inventors
Lan Guo